Literature DB >> 26101225

Intracellular Catabolism of an Antibody Drug Conjugate with a Noncleavable Linker.

Brooke M Rock1, Mark E Tometsko1, Sonal K Patel1, Kevin J Hamblett1, William C Fanslow1, Dan A Rock2.   

Abstract

Antibody drug conjugates are emerging as a powerful class of antitumor agents with efficacy across a range of cancers; therefore, understanding the disposition of this class of therapeutic is crucial. Reported here is a method of enriching a specific organelle (lysosome) to understand the catabolism of an anti-CD70 Ab-MCC-DM1, an antibody drug conjugate with a noncleavable linker. With such techniques a higher degree of concentration-activity relationship can be established for in vitro cell lines; this can aid in understanding the resultant catabolite concentrations necessary to exert activity.
Copyright © 2015 by The American Society for Pharmacology and Experimental Therapeutics.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26101225     DOI: 10.1124/dmd.115.064253

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  5 in total

1.  Determination of Cellular Processing Rates for a Trastuzumab-Maytansinoid Antibody-Drug Conjugate (ADC) Highlights Key Parameters for ADC Design.

Authors:  Katie F Maass; Chethana Kulkarni; Alison M Betts; K Dane Wittrup
Journal:  AAPS J       Date:  2016-02-24       Impact factor: 4.009

2.  Measurement and Mathematical Characterization of Cell-Level Pharmacokinetics of Antibody-Drug Conjugates: A Case Study with Trastuzumab-vc-MMAE.

Authors:  Aman P Singh; Dhaval K Shah
Journal:  Drug Metab Dispos       Date:  2017-08-18       Impact factor: 3.922

3.  Evolution of Antibody-Drug Conjugate Tumor Disposition Model to Predict Preclinical Tumor Pharmacokinetics of Trastuzumab-Emtansine (T-DM1).

Authors:  Aman P Singh; Katie F Maass; Alison M Betts; K Dane Wittrup; Chethana Kulkarni; Lindsay E King; Antari Khot; Dhaval K Shah
Journal:  AAPS J       Date:  2016-03-30       Impact factor: 4.009

4.  Aberrant intracellular metabolism of T-DM1 confers T-DM1 resistance in human epidermal growth factor receptor 2-positive gastric cancer cells.

Authors:  Hongbin Wang; Wenqian Wang; Yongping Xu; Yong Yang; Xiaoyan Chen; Haitian Quan; Liguang Lou
Journal:  Cancer Sci       Date:  2017-05-23       Impact factor: 6.716

5.  Effects of microtubule-inhibiting small molecule and antibody-drug conjugate treatment on differentially-sized A431 squamous carcinoma spheroids.

Authors:  Kenneth R Durbin; M Shannon Nottoli; Gary J Jenkins
Journal:  Sci Rep       Date:  2020-01-22       Impact factor: 4.379

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.